Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Adam C CalawayClint Cary

Abstract

Three cycles of bleomycin, etoposide, and cisplatin (BEP × 3) or four cycles of etoposide and cisplatin (EP × 4) are first-line chemotherapy regimens for men with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk germ cell tumors (GCTs). We determined whether inclusion of bleomycin affected pulmonary and operative morbidity after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We queried our database to identify IGCCCG good-risk patients who received BEP × 3 or EP × 4 induction chemotherapy before PC-RPLND from 2006 to 2016. Patients who received combination regimens were excluded. The primary outcomes of interest were pulmonary morbidity (prolonged intubation, reintubation, supplemental oxygen use, intensive care unit stay) and operative morbidity (operative time, length of stay, concomitant procedures, estimated blood loss). We analyzed 234 patients (191 BEP × 3 v 43 EP × 4). All patients were extubated immediately after the operation. None were reintubated or discharged on oxygen. Two patients in each cohort required an intensive care unit stay for nonpulmonary reasons. Patients treated with BEP required shorter use of supplemental oxygen (0.99 v 1.63 days; P = .005). No significant dif...Continue Reading

References

Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H Einhorn
Jun 4, 1987·The New England Journal of Medicine·S D WilliamsP J Loehrer
Aug 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BoslR Carey
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H EinhornF A Greco
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerD Trump
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A LeviZ Kerestes
Mar 1, 1995·The Journal of Urology·J BanielJ P Donohue
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F BajorinP Sogani
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M O'SullivanA Horwich
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen D W BeckJohn P Donohue
Mar 14, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S CulineUNKNOWN Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP)
Oct 21, 2009·BJU International·Christian WinterPeter Albers
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jakob LauritsenGedske Daugaard
Sep 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Praveen RanganathLawrence H Einhorn

❮ Previous
Next ❯

Citations

Jul 31, 2019·Japanese Journal of Clinical Oncology·Satoshi NittaHiroyuki Nishiyama
Jan 23, 2019·Current Oncology Reports·Costantine AlbanyClint Cary
Jul 7, 2019·The Urologic Clinics of North America·Clint CaryTimothy A Masterson
Mar 10, 2021·Nature Reviews. Urology·Michal ChovanecGedske Daugaard

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.